This FSH study is relevant background for gonadotropin research, but it is not an hMG trial. Preserving that identity distinction prevents evidence from being assigned to the wrong intervention. Primary report
Study snapshot
The multicenter open randomized study compared recombinant FSH with highly purified urinary FSH. Of 168 recruited patients, 155 received FSH and 137 reached hCG administration. The authors reported no statistically significant efficacy differences, despite directional trends in several outcomes. Ovarian hyperstimulation syndrome occurred in both groups. Primary report
Our appraisal: keep the flow and uncertainty together
Recruitment, treatment initiation, trigger administration, retrieval, and transfer are different milestones. Reporting only the final subset could conceal earlier cancellations. A reader should ask which population supplies each numerator and denominator, and whether the analysis preserves randomized assignment.
Several outcomes leaning in the same direction can look persuasive in a summary. That pattern is not a substitute for the specified comparison and its uncertainty. Nor does failure to detect a difference prove that the formulations are equivalent; an equivalence question needs an appropriate design and margin.
The presence of adverse events in both groups also deserves reporting without overinterpretation. Similar percentages in a modest trial cannot establish identical risk, particularly for uncommon serious outcomes. Event severity, ascertainment, and follow-up are part of the safety question.
Finally, a formulation comparison should not be expanded into a class-wide ranking. The tested preparations, treatment sequence, eligibility criteria, and assisted-reproduction practices define the evidence. This historical trial supports a careful account of its findings, not a claim that one gonadotropin is universally best or interchangeable with a research catalog product.
Frequently asked questions
Did this trial compare hMG with FSH?
No; it compared two FSH preparations.
Did every recruited participant receive treatment?
No.
Did every treated participant reach hCG administration?
No.
Were significant efficacy differences reported?
No.
Does that prove equivalence?
No.
Were hyperstimulation events absent?
No; they occurred in both groups.
What is the central reporting requirement?
Attach each outcome to its analysis population and uncertainty.